AbbVie (ABBV) Q4 FY2024 earnings: revenue $15.1 billion, up 5.6% on the year
AbbVie Inc. (ABBV) reported revenue of $15.1 billion for Q4 FY2024, the quarter ended 31 December 2024, up 5.6% on the same quarter a year earlier. Net income was -$22 million, and diluted earnings per share $-0.02. The figures are the company's own, from the 10-K it filed with the SEC on 14 February 2025.
Revenue
$15.1 billion
+5.6% on the year · +4.4% on the quarter
Q1 FY2023Q4 FY2024
Operating margin
-9.9%
22.3% a year earlier
Q1 FY2023Q4 FY2024
Net income
-$22 million
Q1 FY2023Q4 FY2024
Diluted EPS
-$0.02
Q1 FY2023Q4 FY2024
this quarterthe same quarter a year earlierHover a bar for its figure.
Income statement (profit and loss)
$ million
Q4 FY2024
Q3 FY2024
Q4 FY2023
On the quarter
On the year
Last 8 quarters
Revenue
15,102
14,460
14,301
+4.4%
+5.6%
Cost of revenue
4,396
4,212
5,704
+4.4%
-22.9%
Gross profit
10,706
10,248
8,597
+4.5%
+24.5%
Gross margin
70.9%
70.9%
60.1%
Research and development
6,774
2,130
1,927
+218.0%
+251.5%
Selling, general and administrative
3,855
4,205
3,193
-8.3%
+20.7%
Operating income
-1,490
3,831
3,195
Operating margin
-9.9%
26.5%
22.3%
Interest expense
702
720
564
-2.5%
+24.5%
Pre-tax income
-2,269
2,084
1,212
Income tax
-2,246
520
388
Effective tax rate
n/a
25.0%
32.0%
Net income
-22.0
1,561
822
Net margin
-0.1%
10.8%
5.7%
Diluted EPS
-$0.02
$0.88
$0.46
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q4 FY2024
Q3 FY2024
Q4 FY2023
On the quarter
On the year
Last 8 quarters
Operating cash flow
7,048
5,447
4,753
+29.4%
+48.3%
Capital expenditure
291
249
205
+16.9%
+42.0%
Free cash flow
6,757
5,198
4,548
+30.0%
+48.6%
Free cash flow margin
44.7%
35.9%
31.8%
Cash from investing
-1,874
-8,256
-800
Cash from financing
-6,861
-3,072
-4,449
Depreciation and amortisation
2,137
2,091
2,085
+2.2%
+2.5%
Share-based compensation
164
181
125
-9.4%
+31.2%
Buybacks
358
17.0
3.0
+2,005.9%
+11,833.3%
Dividends paid
2,752
2,751
2,626
+0.0%
+4.8%
Dividend per share
$1.64
$1.55
$1.55
+5.8%
+5.8%
Diluted shares, weighted
n/a
1,772m
n/a
Shares outstanding at period end
1,765m
1,767m
1,766m
-0.1%
-0.1%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q4 FY2024
Q3 FY2024
Q4 FY2023
On the quarter
On the year
Last 8 quarters
Shareholders' equity
3,325
6,032
10,360
-44.9%
-67.9%
Non-controlling interest
39.0
39.0
37.0
0.0%
+5.4%
Short-term borrowings
0.0
n/a
0.0
Debt
66,841
71,079
59,245
-6.0%
+12.8%
Operating lease liabilities
697
n/a
735
-5.2%
Finance lease liabilities
23.0
n/a
27.0
-14.8%
Other liabilities
64,236
66,272
64,307
-3.1%
-0.1%
Total liabilities and equity
135,161
143,422
134,711
-5.8%
+0.3%
Fixed assets
5,134
5,141
4,989
-0.1%
+2.9%
Goodwill
34,956
35,295
32,293
-1.0%
+8.2%
Intangible assets
60,068
66,646
55,610
-9.9%
+8.0%
Investments
310
295
306
+5.1%
+1.3%
Cash and equivalents
5,524
7,257
12,814
-23.9%
-56.9%
Receivables
10,919
11,472
11,155
-4.8%
-2.1%
Inventory
4,181
4,450
4,099
-6.0%
+2.0%
Other assets
14,069
12,866
13,445
+9.4%
+4.6%
Total assets
135,161
143,422
134,711
-5.8%
+0.3%
Questions
What was AbbVie's revenue in Q4 FY2024?
AbbVie (ABBV) reported revenue of $15.1 billion for Q4 FY2024, the quarter ended 31 December 2024, up 5.6% on the same quarter a year earlier.
How much did AbbVie earn in Q4 FY2024?
Net loss for Q4 FY2024 was $22 million, and the diluted loss per share $0.02.
When did AbbVie report Q4 FY2024 results?
AbbVie filed its 10-K for the quarter ended 31 December 2024 with the SEC on 14 February 2025.
Each quarter as filed, linked to its filing. Read moreMoney is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-K for the period ended 31 December 2024, filed 14 February 2025: the filing.